Christina T. Loguidice


COVID-19 Pandemic Restructures Care in CLL

January 12th 2021

As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.

Evolving Data for CLL Set Stage for Frontline Therapy

December 4th 2020

In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.

Making Progress Against Relapsed/ Refractory DLBCL Without CAR T

November 3rd 2020

A panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.

Targeted Therapy Options Transform AML Paradigm

October 9th 2020

An increased understanding of the biologic intricacies of acute myeloid leukemia has led to the identification of more than 100 driver mutations associated with the disease, opening the door for targeted therapies with clinically meaningful outcomes for patients who are not candidates for intensive chemo-therapy regimens.

New Options Mark Major Strides in Treating HER2+ Metastatic Breast Cancer

September 16th 2020

A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.

Prompt Diagnosis Is Vital in Treatment of Tenosynovial Giant Cell Tumors

September 1st 2020

During an OncLive Peer Exchange®, a panel of orthopedic experts provided a comprehensive overview of these tumors, including their epidemiology and differential diagnosis, optimal clinical workup, and the role of surgical management.

Experts Decode the Future of Biosimilars in Breast Cancer

August 25th 2020

During a recent OncLive Peer Exchange®, a panel of hematology-oncology experts discussed some of the challenges surrounding the integration of biosimilars in clinical practice using the breast cancer landscape.

PI3K Inhibitors and Oral Taxanes for Metastatic Breast Cancer: Where Do They Fit In?

August 6th 2020

A panel of experts in breast cancer discuss the emergence of alpelisib, review data from the BYLieve trial, discuss the role of everolimus, and review the emergence of oral taxanes.

Biosimilars Expand Patient Access to Novel Treatments

July 20th 2020

A panel of hematology-oncology experts discuss the emergence of biosimilar use in oncology.

Experts Focus on 6 Life-Prolonging Treatments for mCRPC

July 9th 2020

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.